Form 4: Director James Healy Receives Rapport Therapeutics Options

Director James Healy was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director James Healy acquired 15,200 stock options in Rapport Therapeutics, Inc. (RAPP).
• The options have an exercise price of $35.21 per share.
• The grant date is June 10, 2026, with an expiration date of June 10, 2036.
• The options vest on the earlier of June 10, 2027, or the date of the next Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $35.21 exercise price.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board member retention and alignment with company performance.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard compensation packages for early-to-mid stage biotech companies.
• Vesting schedules tied to annual meetings are common practice for board members in the life sciences industry.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 10, 2027, or the next Annual Meeting of Stockholders.

Key Dates

Keywords

Rapport Therapeutics, RAPP, Form 4, Insider Trading, Stock Options, Director Compensation